文献速递类风湿关节炎

类风湿关节炎与恶性淋巴瘤风险:风险是否仍升高?

Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased?
PubMed 文献 · Arthritis Rheumatol · 2017-01-01

基于瑞典风湿病质量登记1997-2012年12,656例新发类风湿关节炎(RA)患者与10倍匹配人群对照,通过肿瘤登记链接识别淋巴瘤及亚型。RA总体淋巴瘤风险比(HR)为1.6(95%CI 1.2-2.1),按RA病程计算风险未随诊断日历年份下降;甲氨蝶呤或TNF抑制剂使用未增加淋巴瘤风险,诊断后第一年口服糖皮质激素与风险降低相关(HR 0.5,95%CI 0.3-0.9),第一年炎症活动度未预测未来淋巴瘤风险。

要点

  • 新近诊断RA的淋巴瘤总体风险仍升高,HR 1.6(95%CI 1.2-2.1)。
  • 按RA病程计算,淋巴瘤风险未随诊断年份推移而下降。
  • 标准抗风湿治疗包括TNF抑制剂未预测未来淋巴瘤风险。

核心结论

  • 新近诊断RA的平均淋巴瘤风险与历史队列报道的幅度相似。
  • 标准抗风湿治疗包括TNF抑制剂未预测未来淋巴瘤风险。
  • 淋巴瘤亚型分布值得进一步研究。

研究设计与样本

  • 研究基于瑞典风湿病质量登记1997-2012年识别12,656例新发RA患者。
  • 每例患者匹配10名人群对照,并通过链接瑞典癌症登记识别淋巴瘤及亚型。
  • 采用Cox回归评估风险比(HR)。

主要发现

  • RA总体淋巴瘤HR为1.6(95%CI 1.2-2.1)。
  • 按RA病程计算,风险未随诊断日历年份下降。
  • 诊断后第一年使用甲氨蝶呤或曾使用TNF抑制剂未增加淋巴瘤风险(HR 0.9,95%CI 0.4-1.9)。
  • 诊断后第一年口服糖皮质激素与淋巴瘤风险降低相关(HR 0.5,95%CI 0.3-0.9)。
  • 诊断后第一年炎症活动度未预测未来淋巴瘤风险。

关键数值与推荐

  • RA患者总体淋巴瘤HR 1.6(95%CI 1.2-2.1)。
  • 甲氨蝶呤或TNF抑制剂使用与淋巴瘤风险HR 0.9(95%CI 0.4-1.9)。
  • 诊断后第一年口服糖皮质激素与淋巴瘤风险HR 0.5(95%CI 0.3-0.9)。
  • RA患者中慢性淋巴细胞白血病发生频率低于一般人群,霍奇金淋巴瘤发生频率高于一般人群。

临床怎么用

  • 对RA患者应关注淋巴瘤风险,但标准抗风湿治疗包括TNF抑制剂未显示增加风险。
  • 诊断后第一年口服糖皮质激素与淋巴瘤风险降低相关,但需结合临床背景解读。
  • 淋巴瘤亚型分布差异提示临床评估时需注意亚型特征。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with rheumatoid arthritis (RA) are at increased risk of malignant lymphomas with a strong correlation with RA disease severity. Given the changes in RA therapy over recent decades, this study was undertaken to assess whether lymphoma risk remains increased, and if so, to explore risk predictors and lymphoma subtypes. METHODS: We identified 12,656 cases of incident RA in the Swedish Rheumatology Quality Register 1997-2012 and obtained information on therapy and inflammatory activity during the first year after diagnosis. Each patient was matched to 10 population comparator subjects. Through linkage to the Swedish Cancer Register, lymphomas, including subtypes, were identified. We assessed hazard ratios (HRs) using Cox regression. RESULTS: Overall, the HR for lymphoma was increased in RA, to 1.6 (95% confidence interval [95% CI] 1.2-2.1). Taking RA duration into account, risks did not appear to have declined over successive calendar years of RA diagnosis. Neither use of methotrexate the first year after RA diagnosis nor ever use of tumor necrosis factor inhibitors (TNFi) increased lymphoma risk (HR 0.9 [95% CI 0.4-1.9]). Use of oral corticosteroids the first year after RA diagnosis was associated with a reduced risk (HR 0.5 [95% CI 0.3-0.9]). Inflammatory activity during the first year after RA diagnosis did not predict future lymphoma risk. Chronic lymphocytic leukemia occurred less frequently, and Hodgkin's lymphoma occurred more frequently, in RA patients than in the general population. CONCLUSION: The average lymphoma risk in recently diagnosed RA is similar in magnitude to that reported in historical cohorts. Standard antirheumatic treatment including TNFi did not predict future lymphoma risk. Distribution of lymphoma subtypes warrants further investigation.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Hellgren K, Baecklund E, Backlin C, et al. Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased? Arthritis Rheumatol. 2017. PMID: 27992692. doi:10.1002/art.40017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。